NK101 Confirmed to Activate the Immune System in Cancer Patients

As part of the development process, patients graciously agreed to provide blood samples before and after treatment to evaluate the change in their NK and T cell response due to NK101 treatment.  Before treatment, all patients had no detectable NK cell response in laboratory testing.  The cells were present and at normal levels, but lacked detectable function.  While the overall T + NK cell sample had some response, it was below the threshold considered normal by this research assay.

After only 3 infusions, all patients had increased NK and T cell immune response compared to the sample taken before treatment. Generally, the NK cells  and T + NK cells  responded similar to normal donors testing in the same research assay indicating that NK101 has upregulated the patient's immune system.  These data align with Dr. Jewett's hypothesis that loss of NK function is frequently observed in cancer patients, and that restoration of NK function may help in the treatment of cancer.